High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers

By afschroeder • August 9, 2025

Ennin E, Mallepally N, Ali M, Shojaie L, Dewberry S, Trieu M, Torres ETR, Zhou K, Kahn J, Dodge JL, Dara L. High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers. Liver Int. 2025 Sep;45(9):e70255. doi: 10.1111/liv.70255. PMID: 40778804.

Tags: CTLA‐4, Digestive Diseases, Fellow, ILICI, immune‐related adverse events, immunotherapy, liver injury, PD‐1, Publications

Related Posts

Corrigendum to “Subchronic inhalation exposure to ultrafine particulate matter alters the intestinal microbiome in various mouse models” [Environ. Res. 248 (2024) 118242]

Chang C, Gupta R, Sedighian F, Louie A, Gonzalez DM, Le C, Cho JM, Park SK, Castellanos J, Ting TW, Dong TS, Arias-Jayo N, Lagishetty[...]

Effectiveness of transoral endoscopic fundoplication with or without hiatal hernia repair in patients with gerd and chronic cough

Swei E, Almario JA, Dunbar K, Yadlapati R, Parker B, Brewer-Gutierrez O, Janu P, Murray M, Sohagia A, Diehl DL, Khara H, Abu Dayyeh B,[...]

Identification of a PRDM1-regulated T cell network to regulate atherosclerotic plaque inflammation

Jin H, Maas SL, Zou Y, Lu C, Yu B, Huchzermeier R, Nadeau S, Dos Santos J, Gijbels M, Mees BME, Smirnov E, Matic L,[...]